FDA Approves Zituvimet (sitagliptin and metformin hydrochloride) to Treat Adult Patients With Type 2 Diabetes Mellitus
November 06, 2023, Ahmedabad, India --  Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as " Zydus " ) today announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 6, 2023 Category: Drugs & Pharmacology Source Type: news

FDA Approves Zituvio (sitagliptin) for the Treatment of Adult Patients with Type 2 Diabetes Mellitus
AHMEDABAD, India, Oct. 20, 2023 /PRNewswire/ -- Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as ' Zydus ' ) today announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 20, 2023 Category: Drugs & Pharmacology Source Type: news

Drug Makers Agree to Negotiate With Medicare on Prices of 10 Medications
President Biden at the White House on Monday. The first negotiations will be over 10 drugs selected by the administration, including blood thinners Eliquis and Xarelto and the diabetes drugs Jardiance and Januvia. The pharmaceutical companies said they would begin talks even as several of them…#xarelto #medicare #karinejeanpierre #maryland #democrats #republicans (Source: Reuters: Health)
Source: Reuters: Health - October 3, 2023 Category: Consumer Health News Source Type: news

Drugmakers opt in to Medicare drug price negotiations
A pharmacist holds a bottle of the drug Eliquis, made by Pfizer Pharmaceuticals, at a pharmacy in Provo, Utah, January 9, 2020. All drugmakers of the first 10 medicines selected for Medicare drug price negotiations have agreed to participate in the talks, even after many of them sued to halt the…#eliquis #provo #utah #medicare #jardiance #boehringeringelheim #xarelto #januvia #farxiga #enbrel (Source: Reuters: Health)
Source: Reuters: Health - October 2, 2023 Category: Consumer Health News Source Type: news

Akums gets DCGI nod for triple combination diabetes medication
Akums Drugs and Pharmaceuticals has received approval from the Drug Controller General of India (DCGI) for a triple combination diabetes medication. The drug combines Sitagliptin 100, Pioglitazone 15, and Metformin 1000/500 to provide better treatment without the need for multiple drugs. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 27, 2023 Category: Pharmaceuticals Source Type: news

Glucose-Lowering Meds Compared for Use With Metformin in T2DM
MONDAY, Oct. 3, 2022 -- For patients with type 2 diabetes receiving metformin, the addition of glargine and liraglutide is more effective than glimepiride and sitagliptin for achieving and maintaining target glycated hemoglobin levels, while the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 3, 2022 Category: Pharmaceuticals Source Type: news

GRADE Published: Liraglutide Best for Type 2 Diabetes After Metformin GRADE Published: Liraglutide Best for Type 2 Diabetes After Metformin
The US-funded GRADE trial shows liraglutide performed best overall when added to metformin, followed by insulin glargine, with sitagliptin and glimepiride trailing. But SGLT2 inhibitors were not included in study.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 21, 2022 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Pricing authority caps rates of key diabetes drugs
India's drug pricing authority has brought two key anti-diabetic drugs - Sitagliptin-Metformin combination and Linagliptin-Metformin combination - under price control. For a 2.5 mg Linagliptin-metformin tablet, the price has been fixed at 16.17, and for the same combination in 5 mg strength, the price will be 25.33 per tablet. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - August 25, 2022 Category: Pharmaceuticals Source Type: news

FDA: Common Diabetes Drug Januvia May Contain Traces of Carcinogen
FRIDAY, Aug. 12, 2022 -- The popular diabetes drug Januvia may contain traces of a probable carcinogen, but patients should keep using the medication because it could be dangerous to stop taking it, the U.S. Food and Drug Administration announced... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 12, 2022 Category: Pharmaceuticals Source Type: news

Common Diabetes Drug Januvia May Contain Traces of Carcinogen, FDA Says
FRIDAY, Aug. 12, 2022– The popular diabetes drug Januvia may contain traces of a probable carcinogen, but patients should keep using the medication because it could be dangerous to stop taking it, the U.S. Food and Drug Administration... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 12, 2022 Category: General Medicine Source Type: news

Samples of Popular Diabetes Drug Contain Potential Carcinogen, F.D.A. Says
Testing found nitrosamine contamination in some samples of Januvia, but regulators will allow Merck to continue selling the drug for now. (Source: NYT Health)
Source: NYT Health - August 11, 2022 Category: Consumer Health News Authors: Andrew Jacobs Tags: Drugs (Pharmaceuticals) Diabetes Regulation and Deregulation of Industry Shortages Cancer Food and Drug Administration Merck & Company Inc your-feed-healthcare Source Type: news

Januvia's Nitrosamine Contamination; COVID & Type 1 Diabetes; Vegans Who Lift
(MedPage Today) -- Some samples of the type 2 diabetes medication sitagliptin (Januvia) were found to be contaminated with nitrosamine; to avoid a shortage, the FDA is allowing Merck to temporarily distribute sitagliptin containing Nitroso-STG... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - August 10, 2022 Category: Endocrinology Source Type: news

FDA works to avoid shortage of sitagliptin following detection of nitrosamine impurity
To avoid a shortage and help ensure patients have access to an adequate supply of the medicine, FDA will not object to the temporary distribution of sitagliptin containing NTTP above the acceptable intake limit of 37 ng per day, and up to 246.7 ng per day. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 9, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

EU OKs Difelikefalin for CKD-Associated Pruritus, Generic Diabetes Meds EU OKs Difelikefalin for CKD-Associated Pruritus, Generic Diabetes Meds
CHMP adopts positive opinions for a new drug for pruritis associated with chronic kidney disease, two biosimilar insulins, and a generic form of the DPP-4 inhibitor sitagliptin for type 2 diabetes.International Approvals (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - March 1, 2022 Category: Transplant Surgery Tags: Diabetes & Endocrinology News Source Type: news

EU Green Light for Finerenone for CKD, Growth Hormone for Kids EU Green Light for Finerenone for CKD, Growth Hormone for Kids
Positive opinions issued for branded somatrogon and finerenone and for generic versions of sitagliptin/metformin hydrochloride and sapropterin.International Approvals (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - December 20, 2021 Category: Transplant Surgery Tags: Diabetes & Endocrinology News Alert Source Type: news